Vigilare Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Vigilare Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,996	Closed	-$226K	–	149
2022 Q1	$226K	Sell	6,996 -4,800	-41%	-$147K	0.19%	123
2021 Q4	$344K	Sell	11,796 -1,425	-11%	-$43.2K	0.2%	127
2021 Q3	$353K	Buy	13,221 +4,150	+46%	+$111K	0.22%	130
2021 Q2	$279K	Buy	9,071 +1,200	+15%	+$36.8K	0.17%	157
2021 Q1	$206K	Buy	+7,871	New	+$220K	0.15%	178

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Vigilare Wealth Management's SUPN Position: Q2 2022 in Review

Vigilare Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2022, closing a stake of 6,996 shares — an estimated $226K sold.

Vigilare Wealth Management first reported a position in SUPN in Q1 2021 and held it in 5 quarters. The position peaked at $353K in Q3 2021. 225 funds tracked by Wall St. Rank hold SUPN as of Q2 2022.

Vigilare Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Vigilare Wealth Management sold 6,996 Supernus Pharmaceuticals shares in Q2 2022, an estimated $226K.
Vigilare Wealth Management first reported a position in Supernus Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Vigilare Wealth Management's Supernus Pharmaceuticals position peaked at $353K in Q3 2021.
225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2022.

Based on Vigilare Wealth Management's 13F filing for Q2 2022, filed 11 Jul 2022.